Unicycive Therapeutics, Inc.
UNCYHealthcare|Biotechnology|US
$3.55
+0.07 (+2.01%)
DCF Value
$1.81
Tangible Book / Share
$1.98
Cash / Share
$2.28
About
Unicycive Therapeutics, Inc. is a U.S.-based biotechnology company dedicated to the creation of innovative treatments for kidney diseases. Its development pipeline includes Renazorb, a therapy for hyperphosphatemia in chronic kidney disease patients, and UNI 494, which is being developed to treat acute kidney injury. Founded in 2016, the firm is headquartered in Los Altos, California.
Stock Price
-20.8%(1Y)
1M
-12.8%
3M
-30.0%
6M
-55.3%
YTD
-38.5%
1Y
-24.6%
3Y
-41.9%
5Y
-88.3%
Pipeline Summary
1 total trials0
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
Completed: 1
Key Facts
Market Cap$97.2M
Employees21 (-5% YoY)
CEOShalabh K. Gupta
IPO DateJul 12, 2021
Beta1.86
52-Week Range$3.33 – $8.74
Avg Volume974,255
ExchangeNASDAQ
Websiteunicycive.com
Ownership
Float97.4%
Shares Outstanding27.4M
Recent Insider Trades
Manning MeredithAWARD
Oct 28, 202627,000 shares @ $3.76
Manning MeredithAWARD
Oct 28, 20263,350 shares
Manning MeredithOTHER
Oct 1, 20260 shares
Kenkare-Mitra SaraAWARD
May 14, 202647,941 shares
Laumas SandeepAWARD
May 14, 202647,941 shares
Peers
Recent News
Unicycive Therapeutics to Present at the Guggenheim 3rd Annual Healthcare Innovation Conference
Nov 4, 2026 · globenewswire.com
CLASS ACTION DEADLINE TONIGHT: Faruqi & Faruqi, LLP Reminds Unicycive Therapeutics (NASDAQ: UNCY) Investors of Securities Class Action Lawsuit Deadline on November 2, 2026
Nov 2, 2026 · businesswire.com
DEADLINE ALERT for Hims & Hers Health, Inc. (HIMS), Unicycive Therapeutics, Inc. (UNCY), and Papa John's International, Inc. (PZZA): The Law Offices of Frank R. Cruz Reminds Investors of Lead Plaintiff Deadlines in Securities Fraud Class Actions
Nov 2, 2026 · globenewswire.com
Data last updated: Nov 9, 2026, 04:38 AM